Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
NCT ID: NCT00198380
Last Updated: 2024-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
90 participants
INTERVENTIONAL
2005-04-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC
NCT00188617
Iressa as Second Line Therapy in Advanced NSCLC-Asia
NCT00478049
Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand
NCT01130961
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
NCT01203917
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
NCT00455936
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Gefitinib
Gefitinib 250 mg/day, until progression or severe toxicity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gefitinib
Gefitinib 250 mg/day, until progression or severe toxicity
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-resectable disease
* 3-month expected survival
* No prior radiotherapy or chemotherapy
* Age \>= 18 years old
* Performance status \< 4 (WHO)
* Adequate blood biological parameters
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Intergroupe Francophone de Cancerologie Thoracique
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jacques Cadranel, Pr
Role: PRINCIPAL_INVESTIGATOR
Intergroupe Francophone de Cancerologie Thoracique
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Besancon - Pneumologie
Besançon, , France
APHP - CHU Avicenne - Oncologie Medicale
Bobigny, , France
Centre F. Baclesse
Caen, , France
CHU - Pneumologie
Caen, , France
CHU Grenoble - pneumologie
Grenoble, , France
HCL - Croix-Rousse
Lyon, , France
APHP - Saint-Antoine - pneumologie
Paris, , France
Hopital Tenon - Pneumologie
Paris, , France
HCL - Lyon Sud (Pneumologie)
Pierre-Bénite, , France
CHU Saint-Etienne Pneumologie
Saint-Etienne, , France
CHU Lyautey - Pneumologie
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cadranel J, Lavole A, Gounant V, Wislez M. [Bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum]. Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S165-70. French.
Wislez M, Massiani MA, Milleron B, Souidi A, Carette MF, Antoine M, Cadranel J. Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest. 2003 Jun;123(6):1868-77. doi: 10.1378/chest.123.6.1868.
Garfield DH, Cadranel JL, Wislez M, Franklin WA, Hirsch FR. The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac Oncol. 2006 May;1(4):344-59.
Cadranel J, Quoix E, Baudrin L, Mourlanette P, Moro-Sibilot D, Morere JF, Souquet PJ, Soria JC, Morin F, Milleron B; IFCT-0401 Trial Group. IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. J Thorac Oncol. 2009 Sep;4(9):1126-35. doi: 10.1097/JTO.0b013e3181abeb5d.
Wislez M, Antoine M, Baudrin L, Poulot V, Neuville A, Pradere M, Longchampt E, Isaac-Sibille S, Lebitasy MP, Cadranel J. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer. 2010 May;68(2):185-91. doi: 10.1016/j.lungcan.2009.05.021. Epub 2009 Jul 5.
Related Links
Access external resources that provide additional context or updates about the study.
Official website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IFCT-0401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.